Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arcus Biosciences ( (RCUS) ) just unveiled an announcement.
On June 10, 2025, Arcus Biosciences held its annual meeting of stockholders, where key proposals were voted on, including the election of Class I directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. Additionally, the Board of Directors revised the Non-Employee Director Compensation Program, reflecting the company’s ongoing efforts to align its governance and compensation practices with industry standards.
The most recent analyst rating on (RCUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
Spark’s Take on RCUS Stock
According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.
Arcus Biosciences receives a score of 51, primarily due to its financial challenges and valuation concerns. While strong cash reserves and promising clinical developments offer potential upside, the company’s ongoing profitability issues and pipeline risks limit its attractiveness. Technical indicators provide mixed signals, requiring cautious optimism from investors.
To see Spark’s full report on RCUS stock, click here.
More about Arcus Biosciences
Arcus Biosciences, Inc. operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is dedicated to creating novel treatment options for cancer patients, leveraging its expertise in immuno-oncology and precision medicine.
Average Trading Volume: 1,159,059
Technical Sentiment Signal: Sell
Current Market Cap: $1.06B
For an in-depth examination of RCUS stock, go to TipRanks’ Overview page.